Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX Rapport sur les actions

Capitalisation boursière : US$5.3b

Crinetics Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 6/6

Crinetics Pharmaceuticals possède un total de capitaux propres de $833.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $937.4M et de $104.4M.

Informations clés

0%

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$862.67m
Fonds propresUS$832.98m
Total du passifUS$104.39m
Total des actifsUS$937.37m

Mises à jour récentes de la santé financière

Recent updates

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CRNX ( $877.6M ) dépassent ses passifs à court terme ( $53.6M ).

Passif à long terme: Les actifs à court terme de CRNX ( $877.6M ) dépassent ses passifs à long terme ( $50.8M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: CRNX est sans dette.

Réduire la dette: CRNX n'avait aucune dette il y a 5 ans.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CRNX dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CRNX dispose d'une marge de trésorerie suffisante pour 2.2 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 32.6 % chaque année.


Découvrir des entreprises saines